Immediate Impact
24 standout
Citing Papers
HER2-targeted therapies in cancer: a systematic review
2024 Standout
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
2024 Standout
Works of JoAl Mayor being referenced
Evaluation of Safety and Clinically Relevant Drug–Drug Interactions with Tucatinib in Healthy Volunteers
2022
MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial in progress.
2022
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| JoAl Mayor | 74 | 41 | 30 | 17 | 120 | |
| Ashraf Azzabi | 56 | 135 | 26 | 13 | 200 | |
| Erin M. Bange | 107 | 50 | 18 | 20 | 182 | |
| Anna Morelli | 54 | 59 | 28 | 17 | 145 | |
| Nikki S. IJzerman | 76 | 117 | 29 | 17 | 206 | |
| V. Hofmann | 42 | 76 | 24 | 18 | 200 | |
| Antonino Carmelo Tralongo | 113 | 49 | 61 | 19 | 221 | |
| Rajiv Panikkar | 92 | 41 | 33 | 14 | 240 | |
| Mirjam de With | 78 | 27 | 64 | 13 | 169 | |
| Ridhi Gupta | 42 | 44 | 22 | 14 | 157 | |
| Sanne de Wit | 35 | 20 | 44 | 14 | 163 |
All Works
Loading papers...